Through a project to reduce gaps and inequities in lupus care and treatment, ACR work groups have developed five quality measures focused on clinical and patient-reported outcomes and are integrating them into the RISE registry to support patient care and research.
A free, tailored, one-hour series on coding and compliance for G2211 will help rheumatology practices bill correctly with the new add-on code to maximize reimbursements and minimize claim denials or rejections.
Throughout her medical training, Noelle A. Rolle, MBBS, encountered many patients struggling with both rheumatic disease and issues of health equity and access to care. This drew her to rheumatology and, now, to lead the ACR’s Collaborative Initiatives Committee.
How can we ensure patients are receiving care that addresses all of the ways rheumatic disease affects their life? In this ACR Convergence 2023 session, experts discuss the value of a strong interprofessional care team.
In this ACR Convergence 2023 session, experts offered guidance on a selection of diagnostic & treatment challenges rheumatologists may encounter.
With state legislatures now in session, the ACR is working with our partners to ensure that the voice of the rheumatology community is heard. Here is a look at some of the bills we are monitoring and the trends we expect to play out over the 2024 legislative calendar.
2024 is an election year, which means it is more critical than ever that RheumPAC is well equipped to support campaigns and take part in important healthcare discussions on Capitol Hill.
With a special interest in implementation science and health information technology, Christie Bartels, MD, MS, is taking lead of the Committee on Registries & Health Information Technology.
The ACR is reaching out to Medicare Advantage and commercial payers to ensure appropriate reimbursement for the new complex care add-on code, G2211, implemented for outpatient office visits starting Jan. 1, 2024.
In 59,970 twins aged 35 years or older, Magnusson et al. compared how much genetics contributes to osteoarthritis (OA) with the genetic contribution to other rheumatic/musculoskeletal diseases (RMDs) in the same population, while exploring the role of shared genetics in OA and other RMDs. The researchers used data from the Swedish Twin Registry, in addition to the Swedish National Patient Register. They concluded that the heritability (i.e., the total genetic contribution to a trait) of OA is relatively large compared with other rheumatic musculoskeletal diseases.